MAR 03, 2018 12:58 AM PST

Doubting the Wonder Drug

WRITTEN BY: Nouran Amin

Baclofen is a drug used to treat an alcohol use disorder. It has long been debuted as the "Wonder Drug" for several of its unique characteristics. For one, baclofen is secreted from the kidneys, not the liver which is particularly advantageous to individuals suffering from liver disease due to an alcohol use disorder (AUD).


Image: University of Liverpool via TechExplorist.com

Historically, baclofen was developed by Dr. Heinrich Keberle in 1962 initially to treat epilepsy. But because of its muscle relaxant properties, it was used instead for the treatment of spasticity particularly in cases related to multiple sclerosis. It was also used in spinal cord injuries for painful muscle spasms.

So, what is baclofen? Baclofen is a GABA receptor agonist that works to suppress the nervous system from an overdose. It's hypothesized that individuals with an AUD are GABA receptor-deficient and thus taking baclofen may reverse this complication and reduce alcohol dependence.

Image Source: ArcaGeorgia.com

However, the mechanism of action of baclofen particularly in treating AUD, still remains unknown. Such mystery encouraged researchers at the University of Liverpool to re-examine the wonder drug.

Originally, the support of baclofen in treating AUD comes from clinical studies showing a decrease in mood swings, depression, and anxiety. Participants also experienced a reduction in alcohol craving.

Now, addiction researchers at the University of Liverpool are questioning the effectiveness of baclofen. Lead researchers, Dr. Abi Rose and Dr. Andy Jones performed a meta-analysis study of roughly 12 clinical trials to see if baclofen holds true in treating alcohol dependence. The purpose was to re-examine the original clinical study that showed support for baclofen and to compare this study across various variables including the placement of a placebo. The meta-analysis study merged all results together to ensure accuracy and reliability of the effectiveness of baclofen.

The addiction research team found that alcohol dependence was reduced in comparison to a placebo. However, that was not sufficient enough as baclofen did not increase alcohol abstinence over a period of days. It was also found that it did not decrease alcohol craving, anxiety, or depression.

Even though the outcomes of this study were more accurate in comparison to the original clinical trial, there are still issues that need to be examined in these current clinical trials. Dr. Rose of the addiction team states, "The existing trials also differ on a number of factors, such as the dose of baclofen given and the length of treatment. Importantly, the pharmacokinetics of baclofen (how it moves in the body) are not well-understood, so there may be individual factors influencing the effectiveness of baclofen that we do not yet understand." The research claims that the use of baclofen in the treatment of an AUD is ‘premature’.

The results of this study were published in the Addiction journal.

Sources: Science Daily, Addiction

 

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
DEC 14, 2019
Drug Discovery & Development
DEC 14, 2019
Compound in Daffodils Can Help Fight Cancer
Preventing the growth of tumors presents a challenge for scientists in finding a cure to cancer. Now however, researchers from the University Libre de Brux...
DEC 14, 2019
Microbiology
DEC 14, 2019
The Antimicrobial Power of Mucus is Revealed
We produce several liters of mucus every day to cover more than 200 square meters in the human body....
DEC 14, 2019
Drug Discovery & Development
DEC 14, 2019
Converting Wood into Pharmaceutical Compounds
Producing toxic byproducts during the making of pharmaceuticals remains a challenge in the drug manufacturing industry. Normally, increased masses of flamm...
DEC 14, 2019
Drug Discovery & Development
DEC 14, 2019
Drug Seeks To Target Treatment-Resistant Epilepsy
Ever imagined a world where you cannot shower alone, drive by yourself, and even go to work in fear of having the next seizure that can incapacitate you? U...
DEC 14, 2019
Technology
DEC 14, 2019
Can artificial intelligence increase tuberculosis drug development?
It’s no secret that there is a shortage of tuberculosis drug development. To combat this issue, researchers at the University of Michigan designed a ...
DEC 14, 2019
Drug Discovery & Development
DEC 14, 2019
New Injection that Treats Peanut Allergy
Peanut allergies affect between 1 and 3% of the US population. Associated with a heightened risk of severe anaphylactic reactions, oral immunotherapy is th...
Loading Comments...